Beryl Drugs

Which are the latest news on Beryl Drugs?

Why is Beryl Drugs Ltd falling/rising?

As of 05-Sep, Beryl Drugs Ltd's stock price is rising to 24.59, reflecting a 3.15% increase. This growth is driven by strong performance against the Sensex, positive moving averages, and increased investor participation.

As of 05-Sep, Beryl Drugs Ltd's stock price is rising, currently at 24.59, which reflects an increase of 0.75 or 3.15%. This upward movement can be attributed to several key factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 7.29% while the Sensex declined by 0.97%. Similarly, in the past month, Beryl Drugs has shown a robust increase of 11.12%, contrasting with a 2.44% drop in the Sensex.<BR><BR>Additionally, the stock is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a strong bullish trend. There has also been a notable increase in investor participation, with delivery volume rising by 29.12% compared to the 5-day average, suggesting heightened interest and confidence among investors. Overall, these factors contribute to the positive momentum in Beryl Drugs Ltd's stock price.

Who are in the management team of Beryl Drugs?

The management team of Beryl Drugs consists of Sanjay Sethi (Executive Director and Managing Director), Sudhir Sethi (Chairman), Abhinav Naik (Independent Non-Executive Director), and Shreya Saraf (Independent Non-Executive Director).

The management team of Beryl Drugs includes the following individuals:<BR><BR>1. **Sanjay Sethi** - Executive Director, Managing Director, and Promoter<BR>2. **Sudhir Sethi** - Chairman and Non-Executive Director<BR>3. **Abhinav Naik** - Independent Non-Executive Director<BR>4. **Shreya Saraf** - Independent Non-Executive Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

What does Beryl Drugs do?

Beryl Drugs Ltd manufactures, sells, and exports branded and generic pharmaceuticals, classified as a Micro Cap company with a market cap of INR 11 Cr. As of June 2026, it reported net sales of 7 Cr and a net profit of 0 Cr.

Overview:<BR>Beryl Drugs Ltd is engaged in the manufacture, sale, and export of branded and generic pharmaceutical formulations, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>Beryl Drugs Limited was incorporated on August 24, 1993, and acquired the running business of M/s Flora and Fauna Remedies Limited on December 15, 1993. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 7 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 11 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 19.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.22 <BR>Return on Equity: 6.28% <BR>Price to Book: 1.18 <BR><BR>Contact Details:<BR>Address: 133 Kanchan Bag, Indore Madhya Pradesh: 452001 <BR>Tel: 91-731-25076375/3046366 <BR>Email: beryldrugs25@yahoo.com <BR>Website: http://www.beryldurgs.com

Who are the peers of the Beryl Drugs?

Beryl Drugs' peers include Desh Rakshak, Dipna Pharmachem, Starsource Multi, Ortin Global, Unjha Formul., Vivanza Biosci., Ganga Pharma., and Brawn Biotech. Unjha Formul. leads in 1-year returns at 10.70%, while Beryl Drugs has a return of -6.86%.

Peers: The peers of Beryl Drugs are Desh Rakshak, Dipna Pharmachem, Starsource Multi, Ortin Global, Unjha Formul., Vivanza Biosci., Ganga Pharma., and Brawn Biotech.<BR><BR>Quality Snapshot: Below Average management risk is observed at Desh Rakshak, Dipna Pharmachem, Ortin Global, Vivanza Biosci., Ganga Pharma., and Brawn Biotech, while Average management risk is found at Unjha Formul. Excellent growth is noted at Dipna Pharmachem, while Below Average growth is seen at Desh Rakshak, Ortin Global, Beryl Drugs, Ganga Pharma., and Brawn Biotech, and Average growth is present at Vivanza Biosci. Unjha Formul. stands out with Good capital structure, while Below Average capital structure is found at Desh Rakshak, Dipna Pharmachem, Ortin Global, Beryl Drugs, Vivanza Biosci., Ganga Pharma., and Brawn Biotech.<BR><BR>Return Snapshot: Unjha Formul. has the highest 1-year return at 10.70%, while Dipna Pharmachem has the lowest at -73.42%, with Beryl Drugs showing a 1-year return of -6.86%. Additionally, the six-month returns are negative for Dipna Pharmachem, Starsource Multi, Vivanza Biosci., and Ganga Pharma.

How big is Beryl Drugs?

As of 31st August, Beryl Drugs Ltd has a market capitalization of 11.00 Cr, with recent net sales of 21.33 Cr and a net profit of 0.62 Cr. Shareholder's funds are 9.50 Cr and total assets amount to 15.95 Cr as of March 2025.

As of 31st August, Beryl Drugs Ltd has a market capitalization of 11.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Beryl Drugs reported Net Sales of 21.33 Cr and a Net Profit of 0.62 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 9.50 Cr and Total Assets of 15.95 Cr.

Should I buy, sell or hold Beryl Drugs Ltd?

When is the next results date for Beryl Drugs Ltd?

The next results date for Beryl Drugs Ltd is 11 August 2026.

The next results date for Beryl Drugs Ltd is scheduled for 11 August 2026.

Are Beryl Drugs Ltd latest results good or bad?

Beryl Drugs Ltd's latest Q4 FY26 results show a positive turnaround with a net profit of ₹0.56 crores and a 35.71% revenue increase, indicating improved operational efficiency. However, concerns about the company's historical volatility and ongoing challenges suggest that caution is warranted despite this strong quarter.

Beryl Drugs Ltd's latest results for Q4 FY26 show a significant turnaround, indicating a positive trajectory in certain areas. The company reported a net profit of ₹0.56 crores, marking a return to profitability after a previous loss of ₹0.17 crores in the prior quarter. Additionally, revenue increased by 35.71% quarter-on-quarter and 29.22% year-on-year, reaching ₹5.13 crores, which reflects a strong recovery.<BR><BR>The operating margin also improved dramatically to 26.12%, the highest in seven quarters, suggesting enhanced operational efficiency. Furthermore, the profit after tax (PAT) margin rose to 10.92%, up from negative figures in the previous quarter.<BR><BR>However, while these results are encouraging, they come with caveats. The company has exhibited significant volatility in its financial performance over the past several quarters, raising concerns about sustainability. The full-year performance remains troubling, with a decline in annual revenue and persistent challenges in profitability.<BR><BR>Overall, while the latest quarterly results are good in isolation, they highlight a dramatic recovery that must be viewed within the context of the company's historical volatility and ongoing operational challenges. Investors should remain cautious, as a single strong quarter does not necessarily indicate a definitive turnaround.

How has been the historical performance of Beryl Drugs?

Beryl Drugs' historical performance shows fluctuating financial metrics, with net sales peaking at 26.89 Cr in Mar'23 but declining to 21.15 Cr by Mar'25, while total operating income also fell from 27.16 Cr to 22.56 Cr in the same period. Despite a decrease in profits and total assets, cash flow from operating activities improved to 2.00 Cr in Mar'25.

Answer:<BR>The historical performance of Beryl Drugs shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Beryl Drugs' net sales peaked at 26.89 Cr in Mar'23 but declined to 21.15 Cr by Mar'25. Other operating income increased from 0.00 Cr in Mar'19 to 1.41 Cr in Mar'25, contributing to a total operating income that reached a high of 27.16 Cr in Mar'23 before falling to 22.56 Cr in Mar'25. The raw material cost also saw a decline from 14.23 Cr in Mar'23 to 11.12 Cr in Mar'25, while total expenditure decreased from 24.95 Cr in Mar'23 to 19.91 Cr in Mar'25. Operating profit (PBDIT) slightly decreased from 2.68 Cr in Mar'24 to 2.65 Cr in Mar'25, with profit before tax showing a decline from 1.01 Cr in Mar'24 to 0.87 Cr in Mar'25. Profit after tax also decreased from 0.77 Cr in Mar'24 to 0.58 Cr in Mar'25. The company's total assets decreased from 17.39 Cr in Mar'23 to 15.95 Cr in Mar'25, while total liabilities also fell from 17.39 Cr to 15.95 Cr during the same period. Cash flow from operating activities improved to 2.00 Cr in Mar'25, contrasting with previous years where it was zero. Overall, Beryl Drugs has experienced both growth and decline in various financial aspects, reflecting a complex performance trajectory.

Is Beryl Drugs overvalued or undervalued?

As of September 2, 2025, Beryl Drugs is considered very attractive with a PE ratio of 12.71 and an EV to EBITDA of 7.30, indicating it is undervalued compared to peers like Sun Pharma and Divi's Lab, despite a challenging year-to-date performance of -29.05%, as it has achieved a 3-year return of 168.59%, significantly outperforming the Sensex.

As of 2 September 2025, Beryl Drugs has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, with a PE ratio of 12.71, an EV to EBITDA of 7.30, and a ROCE of 10.96%. In comparison, its peers exhibit significantly higher valuations, such as Sun Pharma with a PE ratio of 32.69 and Divi's Lab at 70.48, indicating that Beryl Drugs offers a more favorable investment opportunity relative to its competitors.<BR><BR>Despite a challenging year-to-date performance of -29.05%, Beryl Drugs has shown resilience with a 3-year return of 168.59%, significantly outperforming the Sensex's 36.32% return during the same period. This suggests that the market may not fully recognize the company's potential, further supporting the conclusion that it is undervalued.

Who are the top shareholders of the Beryl Drugs?

The top shareholders of Beryl Drugs include promoter Sanjay Sethi with 10.88% and public shareholder Samir Narendra Gupta with 4%. Individual investors collectively hold 68.69%, with no institutional holdings or pledged shares reported.

The top shareholders of Beryl Drugs include Sanjay Sethi, who is the promoter with the highest holding at 10.88%. The highest public shareholder is Samir Narendra Gupta, holding 4%. Additionally, individual investors collectively hold a significant portion of the company at 68.69%. There are no institutional holdings or pledged promoter shares reported.

What is the technical trend for Beryl Drugs?

As of February 21, 2025, Beryl Drugs is in a bearish trend with moderate strength, indicated by bearish MACD, moving averages, and KST, alongside mildly bearish Bollinger Bands and Dow Theory signals.

As of 21 February 2025, the technical trend for Beryl Drugs has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this assessment include a bearish MACD on the weekly chart, bearish moving averages on the daily timeframe, and a bearish KST on the weekly. Additionally, Bollinger Bands are indicating a mildly bearish trend on both weekly and monthly charts. The Dow Theory shows a mildly bearish stance on the weekly but no trend on the monthly, further supporting the bearish outlook.

Has Beryl Drugs declared dividend?

No Dividend History Available